Literature DB >> 29653163

Epstein-Barr Virus as a Potential Etiology of Persistent Bladder Inflammation in Human Interstitial Cystitis/Bladder Pain Syndrome.

Jia-Fong Jhang1, Yung-Hsiang Hsu2, Chih-Wen Peng3, Yuan-Hong Jiang1, Han-Chen Ho4, Hann-Chorng Kuo5.   

Abstract

PURPOSE: Interstitial cystitis/bladder pain syndrome is characterized by bladder inflammation without bacterial infection. Although viral infection is a potential etiological cause, few studies have been reported.
MATERIALS AND METHODS: Bladder specimens were obtained from patients with interstitial cystitis/bladder pain syndrome and from patients with stress urinary incontinence as controls. Bladder specimens were tested for Epstein-Barr encoded RNAs by in situ hybridization and for Epstein-Barr DNA by quantitative real-time polymerase chain reaction, serology and immunohistochemical staining.
RESULTS: Enrolled in study were 16 patients with interstitial cystitis/bladder pain syndrome and Hunner lesions, 23 without interstitial cystitis/bladder pain syndrome or Hunner lesions and 10 controls. The positive rate of Epstein-Barr encoded RNA on in situ hybridization in bladder specimens from patients with vs without interstitial cystitis/bladder pain syndrome and Hunner lesions was 50% vs 8.6%. No Epstein-Barr encoded RNA was found in control specimens. On quantitative real-time polymerase chain reaction Epstein-Barr DNA was detected in 68.8% vs 16.7% of bladder specimens in patients with vs without interstitial cystitis/bladder pain syndrome and Hunner lesions. The median viral load was 1,836 copies per ml (range 216 to 75,144). Only 1 control specimen was Epstein-Barr positive on quantitative real-time polymerase chain reaction. All serum samples from patients with interstitial cystitis/bladder pain syndrome showed past Epstein-Barr viral infection. Epstein-Barr infection was present in 87.5% vs 17.4% of bladder specimens from patients with vs without interstitial cystitis/bladder pain syndrome and Hunner lesions for a total of 46.2% with interstitial cystitis/bladder pain syndrome. Immunohistochemical staining of CD3 and CD20 revealed that Epstein-Barr infection was mainly restricted to T lymphocytes in bladders showing interstitial cystitis/bladder pain syndrome.
CONCLUSIONS: Bladder Epstein-Barr infection in T cells may be linked to the pathogenesis of persistent inflammation in patients with interstitial cystitis/bladder pain syndrome.
Copyright © 2018 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epstein-Barr virus infections; T-lymphocytes; cystitis; etiology; interstitial; urinary bladder

Mesh:

Year:  2018        PMID: 29653163     DOI: 10.1016/j.juro.2018.03.133

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  12 in total

Review 1.  [The role of the microbiome in urology].

Authors:  G Magistro; J Marcon; L Eismann; Y Volz; C G Stief
Journal:  Urologe A       Date:  2020-12       Impact factor: 0.639

2.  298 THE INCIDENCE OF NEW OR WORSENING OAB SYMPTOMS IN PATIENTS WITH PRIOR SARS COV-2 INFECTION: A COHORT STUDY.

Authors:  L Hoang Roberts; B Zwaans; K Peters; M Chancellor; P Padmanabhan
Journal:  Continence (Amst)       Date:  2022-07-08

3.  Can We Use Urinary Cytokine/Chemokine Analysis in Discriminating Ulcer-Type Interstitial Cystitis/Bladder Pain Syndrome?

Authors:  Yuan-Hong Jiang; Jia-Fong Jhang; Hann-Chorng Kuo
Journal:  Diagnostics (Basel)       Date:  2022-04-27

Review 4.  Interstitial cystitis/bladder pain syndrome: The evolving landscape, animal models and future perspectives.

Authors:  Yoshiyuki Akiyama; Yi Luo; Philip M Hanno; Daichi Maeda; Yukio Homma
Journal:  Int J Urol       Date:  2020-04-04       Impact factor: 3.369

5.  Multimodal Single-Cell Analyses Outline the Immune Microenvironment and Therapeutic Effectors of Interstitial Cystitis/Bladder Pain Syndrome.

Authors:  Fei Su; Wei Zhang; Lingfeng Meng; Wei Zhang; Xiaodong Liu; Xiaorui Liu; Meng Chen; Yaoguang Zhang; Fei Xiao
Journal:  Adv Sci (Weinh)       Date:  2022-04-25       Impact factor: 17.521

6.  The Urinary Tract Microbiome in Male Genitourinary Diseases: Focusing on Benign Prostate Hyperplasia and Lower Urinary Tract Symptoms.

Authors:  Myung Soo Kim; Seung Il Jung
Journal:  Int Neurourol J       Date:  2021-01-19       Impact factor: 2.835

Review 7.  Low-Energy Shock Wave Plus Intravesical Instillation of Botulinum Toxin A for Interstitial Cystitis/Bladder Pain Syndrome: Pathophysiology and Preliminary Result of a Novel Minimally Invasive Treatment.

Authors:  Yuan-Hong Jiang; Jia-Fong Jhang; Yu-Khun Lee; Hann-Chorng Kuo
Journal:  Biomedicines       Date:  2022-02-07

8.  The NLRP3 Inflammasome Inhibitor Dapansutrile Attenuates Cyclophosphamide-Induced Interstitial Cystitis.

Authors:  Sonia Kiran; Ahmed Rakib; Udai P Singh
Journal:  Front Immunol       Date:  2022-06-03       Impact factor: 8.786

Review 9.  The Potential Role of Urinary Microbiome in Benign Prostate Hyperplasia/Lower Urinary Tract Symptoms.

Authors:  Seong Hyeon Yu; Seung Il Jung
Journal:  Diagnostics (Basel)       Date:  2022-08-01

Review 10.  Biomarkers in the Light of the Etiopathology of IC/BPS.

Authors:  Jochen Neuhaus; Mandy Berndt-Paetz; Andreas Gonsior
Journal:  Diagnostics (Basel)       Date:  2021-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.